Requip XL

See also: Generic Requip

Requip XL is a brand name of ropinirole, approved by the FDA in the following formulation(s):

REQUIP XL (ropinirole hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: SMITHKLINE BEECHAM
  
  Approval date: June 13, 2008
  
  Strength(s): EQ 2MG BASE ^[RLD], EQ 4MG BASE, EQ 8MG BASE
  


• 
  Manufacturer: SMITHKLINE BEECHAM
  
  Approval date: October 31, 2008
  
  Strength(s): EQ 12MG BASE
  


• 
  Manufacturer: SMITHKLINE BEECHAM
  
  Approval date: April 10, 2009
  
  Strength(s): EQ 6MG BASE
  

Has a generic version of Requip XL been approved?

No. There is currently no therapeutically equivalent version of Requip XL available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Requip XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tablets with controlled-rate release of active substances
  Patent 5,422,123
  Issued: June 6, 1995
  Inventor(s): Conte; Ubaldo & La Manna; Aldo & Colombo; Paolo
  Assignee(s): Jagotec AG
  Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
  
  Patent expiration dates:
  
  
  • June 6, 2012
    
    ✓ 
    Drug product
  
  



• 
  Hydrophilic/lipophilic polymeric matrix dosage formulation
  Patent 7,927,624
  Issued: April 19, 2011
  Inventor(s): Vergnault; Guy & Grenier; Pascal & Maggi; Lauretta & Conte; Ubaldo
  Assignee(s): Jagotec AG
  An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.
  
  Patent expiration dates:
  
  
  • December 2, 2021
    
    ✓ 
    Patent use: A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 13, 2011 - NEW DOSAGE FORM
  
  

See also...

• Requip XL Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Requip XL Consumer Information (Cerner Multum)
• Requip XL Advanced Consumer Information (Micromedex)
• Ropinirole Consumer Information (Wolters Kluwer)
• Ropinirole Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Ropinirole Consumer Information (Cerner Multum)
• Ropinirole Advanced Consumer Information (Micromedex)
• Ropinirole Hydrochloride AHFS DI Monographs (ASHP)